Clinical trial readout dates for Teleflex Incorporated, compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$5.8B
Cash & investments$430Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-05
In progress, no date published
Phase 3BiPASS (Illuccix)
Biopsy of the Prostate Avoidance Stratification Study
date not published
Ongoing
Cash position
Teleflex Incorporated reported $430M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $927M for that quarter.